Wed, Aug 20, 2014, 10:47 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • yaahhuh yaahhuh Apr 10, 2014 10:14 PM Flag

    In A Shaky Biotech Market, Alnylam's Prospects Are Getting Stronger

    From: Seeking Alpha article -Apr. 7, 2014 12:10 PM ET | About: ALNY

    In A Shaky Biotech Market, Alnylam's Prospects Are Getting Stronger

    Specific to Alnylam (ALNY), though, I would argue the company has never been stronger. The company is on pace to exceed its target of having five compounds in human studies by the end of 2015 ("5 x 15"), and a recent deal with Sanofi (SNY) gives Alnylam development funding, a motivated commercial partner, and the perception that it has been vetted by a large pharmaceutical company with a significant presence in rare diseases.

    Alnylam is absolutely a risky pick, and investors should not ignore the risk that not only may the company's drugs fail in the clinic or in the marketplace, but that investors indiscriminately bailing out of the sector could weigh on the share price at times. On the flip side, I cannot ignore that Alnylam has multiple potential billion dollar-plus drugs in the clinic and a very strong R&D position in what could prove to be one of the next major therapeutic alternatives. With that, I see almost 50% upside in Alnylam shares today.

    Sentiment: Hold

 
ALNY
67.33-0.72(-1.06%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.